The clinical rationale for expanding access is grounded in shifting epidemiology. Hepatocellular carcinoma, the most common primary liver cancer, has risen substantially in incidence and mortality in the United States and worldwide, increasingly driven by non-viral causes such as metabolic-dysfunction-associated steatotic liver disease, or MASLD. Current American Association for the Study of Liver Diseases guidelines do not recommend routine surveillance for most MASLD patients unless they develop cirrhosis, which means many tumors are caught at later stages. With roughly two-thirds of patients falling into the intermediate or advanced categories of the Barcelona Clinic Liver Cancer staging system, where liver-directed therapies play a central and evolving role, the authors contend that improved access to these treatments is essential to meet a growing healthcare burden.

Radioembolization works by threading millions of microscopic beads loaded with yttrium-90, a beta-emitting radionuclide, through the hepatic artery directly into the vessels feeding a tumor. The radiation travels an average of only a few millimeters in tissue, delivering tumoricidal doses while sparing much of the surrounding liver. Over the past two decades the technique has moved from lobar, body-surface-area-based dosing toward superselective, segmental delivery guided by personalized dosimetry. That shift has transformed its role. Radiation segmentectomy, in which an ablative dose is concentrated in one or two liver segments, has created a curative-intent option for selected patients with early-stage disease who are not ideal candidates for surgery or thermal ablation.

The evidence supporting this evolution is now substantial. Early randomized trials comparing radioembolization with the drug sorafenib, including SARAH and SIRveNIB, showed no overall survival advantage, but those studies predate modern patient selection and dosimetry. A post hoc analysis of SARAH found that patients receiving adequate tumor absorbed dose derived greater benefit, pointing directly at dosimetry as the missing variable. The randomized DOSISPHERE-01 trial then demonstrated improved objective response rates and overall survival when dosing was personalized to maximize tumor absorbed dose compared with standard approaches. Studies such as LEGACY, RASER, and DOORwaY90 have since shown high response rates with segmental high-dose delivery, and comparative trials including TRACE and PREMIERE suggest potential advantages over chemoembolization in selected patients, including longer time to progression and fewer treatment sessions.

In the transplant arena, radioembolization has become the most commonly used liver-directed therapy in the United States for bridging and downstaging patients awaiting a new liver. A key metric is complete pathologic necrosis, the disappearance of viable tumor on examination of the explanted liver, which radioembolization achieves at consistently high rates compared with other locoregional therapies and which is associated with better post-transplant outcomes. Emerging data suggest, however, that factors beyond mean tumor dose, such as microsphere-specific activity, particle density, and spatial dose heterogeneity, may independently influence the radiobiologic effect. Because glass and resin microspheres differ substantially in these properties, the authors caution that dose targets and delivery strategies may not be interchangeable across platforms, and future guidelines should account for microsphere type, treated vascular territory, and the intended biologic endpoint.

Regulatory milestones have accelerated adoption. The U.S. Food and Drug Administration granted premarket approval for TheraSphere glass microspheres for unresectable hepatocellular carcinoma in March 2021, while SIR-Spheres resin microspheres, approved in 2002 for colorectal liver metastases, received an added unresectable HCC indication in 2025. Unified practice parameters, including the 2023 ACR-ABS-ACNM-ARS-SIR-SNMMI practice parameter, have standardized patient selection, lung shunt assessment, dose planning, and radiation safety, making results more reproducible across centers. But standardization also raises the bar: a credible program now requires reliable nuclear medicine collaboration, dosimetry support, trained interventional radiology staff, consistent imaging protocols, and a system for tracking outcomes.

The operational heart of the review is a detailed team structure. Interventional radiologists lead protocol development, case selection, dosimetry oversight, and informed consent, supported by nurses, technologists, and advanced practice providers. Medical physicists implement and audit dosimetric protocols; nuclear medicine physicians and radiopharmacists manage the radiotracer and interpret lung shunt and post-therapy imaging; and hepatology, oncology, transplant surgery, diagnostic radiology, and palliative care contribute through a multidisciplinary tumor board. A standardized pathway converts this structure into reproducible care, moving patients from referral intake through tumor board presentation, interventional radiology clinic visits, mapping angiography with technetium-99m MAA imaging, dosimetric review, treatment, and structured follow-up. Quality is monitored with pragmatic metrics: process measures such as time from referral to treatment and a work-up completion rate above 90 percent as an aspirational benchmark, clinical measures such as response rates and downstaging success, and safety measures tracking unplanned admissions, gastrointestinal ulceration, radiation pneumonitis, and deterioration in liver function within 90 days.

A recurring theme is the central role of the dedicated nurse coordinator, who serves as the program’s operational and clinical liaison. Within the boundaries of nursing scope of practice, the coordinator navigates patients through the pathway, prepares families for the logistics of separate mapping and treatment visits, coordinates authorizations and appointments across services, and conducts structured post-procedure check-ins to catch symptoms early. The authors emphasize that this role often becomes the most continuous point of contact for patients and families, providing emotional support and a trusted space for questions throughout a protracted treatment journey. Patient decision aids, including bilingual tools developed by the Interventional Initiative, have been shown in clinical trials to improve understanding and satisfaction before informed consent conversations.

The review also confronts the business case frankly. Hospitals that refer radioembolization cases out lose revenue from the entire episode of care, including imaging, clinic visits, mapping procedures, nuclear medicine studies, and follow-up. A make-versus-buy analysis must weigh fixed assets such as angiography suites and dosimetry software against variable costs and projected volume; a program may be profitable per case yet unjustifiable at very low volume near a high-quality regional center. Conversely, rural or geographically isolated hospitals may justify an in-house program even at lower volume if local treatment reduces travel burden and shortens time to therapy, considerations that carry particular weight for nonprofit and government systems. The authors propose a three-phase implementation timeline: stakeholder engagement, protocol development, and device-specific training; treatment of an initial cohort of straightforward cases with real-time dashboards tracking patient flow; and early outcomes review culminating in an internal playbook that consolidates workflows and supports onboarding and growth.

Ultimately, the authors argue that a high-performing radioembolization practice is best understood as a service line rather than a procedure. Durable, reproducible outcomes require an intentional infrastructure linking multidisciplinary decision-making, evidence-based selection, personalized dosimetry, nuclear medicine partnership, trained procedural teams, coordinated nursing navigation, and longitudinal outcome tracking. When leadership support, patient-centered education, and continuous process improvement are deliberately built in, the therapy can expand access to advanced liver-directed treatment, reduce fragmentation of care, and strengthen the broader hepatobiliary oncology ecosystem. The future of radioembolization, they conclude, depends not only on better devices, dosimetry, and trials, but on building systems capable of delivering the therapy safely, consistently, and in alignment with patient goals.

Subject of Research: Building and sustaining high-performing yttrium-90 radioembolization programs for liver cancer

Article Title: Building a high-performing yttrium-90 radioembolization practice: from evidence to experience

Article References: Malone, C., Friend, C., Schmitt, B., Siskin, G., & Newton, I. (2026). Building a high-performing yttrium-90 radioembolization practice: from evidence to experience. CVIR Oncology, 2(1), Article 30. https://doi.org/10.1007/s44343-026-00064-0

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00064-0

Keywords: yttrium-90, radioembolization, hepatocellular carcinoma, radiation segmentectomy, personalized dosimetry, liver-directed therapy, interventional radiology, nuclear medicine, transplant bridging, multidisciplinary care, nurse coordinator, program development

The study, published in CVIR Oncology, draws on the CIRT registry spanning 27 sites across eight European countries and its French counterpart, CIRT-FR, which was conducted to help the French Health Authority evaluate reimbursement of yttrium-90 resin microspheres. Both registries were designed to capture real-world clinical practice rather than the tightly scripted conditions of a randomized trial, and that realism is precisely what makes the findings interesting. Physicians recorded their planned treatment intent at the start of therapy, but the researchers later reclassified each patient’s actual trajectory using predefined criteria covering transplantation, ablation, resection, or a sustained complete response lasting at least one year as measured by modified RECIST criteria.

The headline numbers tell a story about the gap between intention and outcome. Although 229 of the 615 patients, roughly 37 percent, were initially slated for curative-intent treatment pathways, only 40 patients, or 6.5 percent, ultimately met the retrospective curative-intent definition, while 93 percent were classified as palliative. Of those 40, half went on to liver transplantation after TARE, seven received ablation and two underwent resection. Most remarkably, 11 patients, 27.5 percent of the curative group, required no further treatment at all because TARE alone had produced a complete tumor response documented for at least a year.

That last figure carries particular weight given how the authors framed their expectations. Among 32 patients whose a priori plan was radiation segmentectomy, meaning planned curative yttrium-90 monotherapy, only one ultimately achieved a curative classification through subsequent transplantation. In other words, the patients who ended up cured by radiation alone were rarely the ones selected for that purpose in advance. Their complete responses were, in a sense, discovered rather than engineered, which the authors say underscores how little consensus currently exists on who will convert to a curative pathway after radioembolization and how urgently refined conversion criteria are needed.

The statistical analysis offers some clues. In multivariable logistic regression, three factors independently predicted placement in the curative-intent group: an ECOG performance status of zero, corresponding to fully active patients, carried an odds ratio of 0.44; having one to three tumors yielded an odds ratio of 0.39; and a total tumor volume below 150 cubic centimeters produced an odds ratio of 0.40. That 150 cubic centimeter threshold emerged from receiver operating characteristic analysis as one of two optimal cut points for separating curative from palliative patients, and it was selected for its higher specificity of 0.725. Notably, 72.5 percent of curatively treated patients fell below this volume, which is substantially larger than the roughly 65 cubic centimeter ceiling imposed by the classic Milan criteria for transplantation eligibility.

This discrepancy is central to the paper’s argument. The Milan criteria, which have governed transplant selection for hepatocellular carcinoma for nearly three decades, rest almost entirely on morphometric measurements, and the authors found no significant differences between their curative and palliative groups on Milan-based eligibility before treatment. Around 80 percent of the curatively managed patients were outside Milan criteria before TARE. The implication is that radioembolization can shrink tumors enough to pull patients back within transplant boundaries, and that tumor volume thresholds well beyond Milan’s limits, combined with biological markers such as alpha-fetoprotein and the ALBI grade of liver function, may better identify who stands to benefit. The authors point to emerging tools like the Metroticket 2.0 model as the kind of finer-grained metrics the field needs.

Dosimetry adds another technical layer to the story. Because absorbed radiation doses were not prospectively collected in the original registries, the team recalculated them retrospectively using the simplified Medical Internal Radiation Dose formula, dividing administered activity by tumor mass. Their surrogate analysis found that absorbed doses above 400 grays correlated with longer survival, a threshold repeatedly associated with complete response in prior literature. Crucially, 92.3 percent of patients who received doses above that level had tumors under 150 cubic centimeters, suggesting that the concentration of radiation achievable in smaller, more selectively targeted volumes is what drives these dramatic responses. Yet the data also showed that doses exceeding 400 grays remained effective in tumors up to about 150 cubic centimeters, roughly 6.6 centimeters in diameter, larger than many earlier studies had considered treatable at such intensities.

Survival outcomes reinforce the signal. Median overall survival was not reached in the complete response, resection, and ablation subgroups by the end of follow-up, and in the transplantation subgroup, 75 percent and 85 percent survival percentiles were reached at 37.1 and 11.4 months respectively, with only one death recorded in the resection and ablation group and none in the complete response group. By contrast, the palliative group’s median survival of 16.1 months compares favorably with the 8.0 and 8.8 months reported in the landmark SARAH and SIRveNIB randomized trials of radioembolization versus sorafenib in advanced disease, and aligns with more recent prospective figures of 13.9 months. The real-world palliative performance alone is notable, but the theoretical cure fractions achieved in a minority of patients are what will spark debate.

The authors are careful about the limits of their evidence. This was an exploratory, retrospective classification layered onto prospective observational data, with no harmonized definition of curative intent when the studies began. Baseline characteristics were collected only before TARE, alpha-fetoprotein levels were missing in more than a fifth of curative patients and more than 40 percent of palliative patients, and dosimetry relied on a surrogate calculation. The heterogeneity of post-TARE curative procedures across different national practices further complicates generalization. Still, the conclusion is clear and consequential: yttrium-90 radioembolization belongs not just in the palliative toolbox but across the full spectrum of curative-intent strategies for hepatocellular carcinoma, whether as a bridge to transplantation, a downstaging tool before resection or ablation, or, in carefully selected patients with small tumor burdens and good performance status, as a standalone therapy capable of eradicating the disease outright. The task now facing the field, the authors argue, is to marry morphometry, tumor biology, and personalized dosimetry into reliable criteria that can identify, before the first microsphere is injected, which patients will be among the lucky few whose cancer never returns.

Subject of Research: Curative-intent transarterial radioembolization with yttrium-90 in hepatocellular carcinoma

Article Title: Hepatocellular carcinoma patients treated with TARE monotherapy or combination therapy with curative intent: a retrospective, exploratory analysis of two European prospective studies

Article References: Helmberger, T., Arnold, D., Loffroy, R., Ronot, M., Sangro, B., Kolligs, F., Pellerin, O., Maleux, G., Peynircioglu, B., Schaefer, N., Bilbao, J. I., de Jong, N., Geyer, M., Zeka, B., Urdaniz, M., & Vilgrain, V. (2026). Hepatocellular carcinoma patients treated with TARE monotherapy or combination therapy with curative intent: a retrospective, exploratory analysis of two European prospective studies. CVIR Oncology, 2(1), Article 5. https://doi.org/10.1007/s44343-026-00035-5

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00035-5

Keywords: hepatocellular carcinoma, TARE, yttrium-90, radioembolization, liver transplantation, radiation segmentectomy, Milan criteria, dosimetry, tumor downstaging, locoregional therapy, complete response, CIRT registry

Radioembolization, also known as selective internal radiation therapy, involves threading tiny radioactive microspheres through the arteries that feed liver tumors, delivering high doses of radiation directly to cancerous tissue while sparing healthy liver. The field has steadily moved toward increasingly selective strategies, with radiation segmentectomy now often favored over whole-liver or lobar approaches because it can treat early hepatocellular carcinoma in an ablative manner. But greater selectivity comes at a price: when a patient has multiple tumors in different liver segments, physicians frequently need to access several separate injection positions within the arterial network, and each repositioning step creates a practical dilemma that has long frustrated operators.

The problem is fundamentally one of contamination. Conventional microcatheters have a single lumen that serves both as the guidewire track and the injection channel. Once radioactive microspheres have passed through that channel, any subsequent manipulation of a guidewire through the same space risks smearing radioactive material onto the wire and, by extension, the sterile field. Current clinical practice therefore mandates discarding the microcatheter after each injection position and inserting a fresh one for the next target vessel. That approach generates additional radioactive waste, extends procedure time, and adds cost, particularly in complex cases where selective catheterization is technically demanding.

The Utrecht team hypothesized that a catheter with two physically separate lumens could eliminate this risk entirely. They employed a 3.2-Fr dual-lumen microcatheter, the Sasuke device from Asahi Intecc in Japan, which was originally designed for cardiac interventions. The device features a rapid-exchange lumen extending from the catheter tip to an exit port located 20 centimeters proximally, which accommodates a 0.016-inch guidewire, and an over-the-wire lumen that runs from the proximal catheter end to an exit port just 6.5 millimeters from the tip, which serves as the microsphere injection pathway. Because the guidewire and the microspheres travel through entirely separate channels, they never come into contact, theoretically eliminating guidewire contamination regardless of how many times the catheter is repositioned.

The technique itself unfolds in a deliberate sequence. After standard femoral arterial access with a 6-Fr sheath, a 6-Fr guiding catheter was advanced into the celiac trunk, since the 3.2-Fr microcatheter is too large to pass through standard 4 to 5 Fr diagnostic catheters. The dual-lumen microcatheter was then navigated to the first target vessel over the guidewire. Once the position was confirmed, the guidewire was retracted so that its tip resided safely within the rapid-exchange lumen, well away from any microspheres. Two microsphere administration systems were connected to the injection lumen through a three-way stopcock, the first dose was delivered, and the lumen was thoroughly flushed with saline. To move to the second site, the guidewire was simply advanced again through its dedicated lumen to steer the catheter to the next target, retracted once more, and the second dose was injected through the same channel.

The first patient was an 80-year-old man with two hepatocellular carcinoma lesions, one in liver segment 4 and one in segment 8, undergoing radioembolization work-up. The dual-lumen microcatheter successfully delivered scout doses of holmium-166 microspheres to both positions, first through the left hepatic artery and then, after repositioning, through the segment 8 artery. Cone-beam computed tomography from both positions demonstrated the expected vascular territories, and subsequent single-photon emission computed tomography confirmed adequate microsphere distribution to both tumors. The total procedure, from vascular access to closure, took 95 minutes, with cumulative fluoroscopy time of 18 minutes and 50 seconds and a total dose-area product of 330 Gy·cm².

The second case put the technique to a therapeutic test. A 79-year-old patient with neuroendocrine tumor liver metastases required treatment doses at two positions, the right hepatic artery and the segment 4 artery. Using a single dual-lumen microcatheter, the team delivered a first therapeutic dose of 4100 MBq of holmium-166 microspheres into the right hepatic artery and then repositioned to deliver a second dose of 3000 MBq into the segment 4 artery. One technical wrinkle emerged: at both injections, pressure inside the administration system rose rapidly to its maximum, indicated by the fluid level in the V-vial climbing to the rubber septum, so the team injected at a substantially reduced rate with roughly 20 seconds of additional time between flushing and microsphere administration to allow pressure normalization. A calibrated dose calibrator confirmed no significant residual activity afterward, and post-procedural imaging verified adequate microsphere distribution. This procedure took just 65 minutes, with 14 minutes and 29 seconds of fluoroscopy and a dose-area product of 86.3 Gy·cm².

Critically, radiation safety monitoring validated the central premise of the approach. As part of standard institutional protocol, all disposable materials, including the guidewire, were surveyed with a contamination monitor after each procedure. In both cases, count rates fell below the institutional threshold of 200 counts per second, the level below which materials can be discarded as regular non-radioactive waste. Catheter repositioning in both procedures was accomplished smoothly without technical difficulties, suggesting that maintaining the guidewire within its own lumen throughout the procedure neither impedes navigation nor compromises delivery precision.

The researchers are candid about the technique’s limitations. The 3.2-Fr outer diameter exceeds the typical 2.7-Fr profile of standard microcatheters, requiring guiding catheters rather than conventional diagnostic ones, a setup change that some centers may need to make. The injection port sits 6.5 millimeters proximal to the catheter tip, meaning the tip must be advanced slightly beyond the intended injection point, which could prove difficult in small vessels, and the protruding tip could theoretically pick up surface contamination. More significantly, the narrow 0.016-inch inner diameter of each lumen generates higher injection pressures than standard microcatheters, and not all microsphere delivery systems tolerate this. The instructions for use of widely used yttrium-90 glass and resin microsphere systems recommend minimum inner diameters of 0.020 and 0.021 inches respectively, making pressure compatibility an important barrier to broader adoption.

Two complementary developments could ease that constraint. Pressure-resistant delivery systems, such as the recently introduced SIROS system for yttrium-90 resin microspheres, may better accommodate narrow-lumen catheters; in a retrospective study of 48 SIROS administrations through a microcatheter with a 0.021-inch inner diameter, mean residual activity was just 4.9 percent, and 94 percent of administrations retained less than 10 percent residual activity with a double-flush protocol. Alternatively, manufacturers could design dual-lumen catheters specifically for microsphere delivery, with a larger dedicated injection lumen and a smaller guidewire channel. The authors also note that delivering predetermined doses at multiple positions currently requires multiple administration systems connected via stopcocks, and point to dose-titration systems such as the Eye90 microsphere platform as potential solutions. Guidewireless steerable microcatheters offer another route around contamination, having achieved guidewire-free catheterization in 93 percent of applications in a 50-patient multicenter trial, but they carry elevated risks of vessel injury and catheter kinking, particularly in tortuous or very wide vessels. The dual-lumen approach retains guidewire support throughout, trading a slightly larger catheter profile for potentially safer navigation.

For now, the findings rest on just two cases performed by a single experienced operator at one institution, without a control group for comparison, so the authors caution that the results do not yet support routine clinical use. Still, the proof of principle is compelling: a single catheter served two injection positions in each patient, no guidewire contamination was detected, and the technique could plausibly cut radioactive waste and procedure time in multi-position treatments. The team, whose work is supported by the European Union-funded IMAGIO consortium under the Innovative Health Initiative, calls for larger studies evaluating the technique with different microspheres and delivery systems, assessing its applicability to more complex multi-position procedures, and directly comparing repositioning time, total procedure duration, and residual activity against conventional single-lumen catheter exchange. If those studies bear out the promise, a device borrowed from the cardiology catheterization lab may become a quiet workhorse of precision liver cancer therapy.

Subject of Research: Dual-lumen microcatheter technique for multi-position radioembolization of liver tumors

Article Title: Dual-lumen microcatheter facilitating multiple injection positions in radioembolization: proof of principle

Article References: Smits, M. L. J., Wijnen, N., Lam, M. G. E. H., de Bruijne, J., & Vonken, E.-J. P. A. (2026). Dual-lumen microcatheter facilitating multiple injection positions in radioembolization: proof of principle. CVIR Oncology, 2(1), Article 28. https://doi.org/10.1007/s44343-026-00055-1

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00055-1

Keywords: dual-lumen microcatheter, radioembolization, guidewire contamination, holmium-166 microspheres, radiation segmentectomy, liver tumors, interventional radiology, hepatocellular carcinoma, microsphere delivery, catheter repositioning, Dual-lumen, microcatheter

The technique is a hybrid of two established concepts in interventional radiology. Radiation segmentectomy delivers an ablative dose of yttrium-90 glass microspheres directly into the artery feeding the tumor, achieving intense local tumor control. Radiation lobectomy, by contrast, treats the entire tumor-bearing lobe with a moderate dose that induces atrophy of the treated parenchyma, redirecting portal blood flow and growth signals to the untreated lobe, which compensates by enlarging. Modified radiation lobectomy combines these effects in a single procedure: a segmental or two-adjacent-segment boost above 190 Gy for tumor control, layered onto a lobar dose between 80 and 120 Gy to drive hypertrophy of the future liver remnant. In this study, the mean lobar prescribed dose was 198 plus or minus 58 Gy, with a mean segmental boost of 226 plus or minus 153 Gy, and patients received an average of 1.6 segmental doses.

The standard alternative for expanding a future liver remnant is portal vein embolization, which reliably induces hypertrophy but offers no direct tumor treatment, leaving a window during which cancer can progress. Transarterial chemoembolization controls tumors but produces less predictable liver growth and typically requires staged procedures. Modified radiation lobectomy uniquely merges tumor control and remnant augmentation in one session, which is why the researchers at an academic medical center in Colorado turned to it for patients whose tumors were unresectable by imaging criteria or biopsy, who had preserved liver function classified as Child-Pugh A, an Eastern Cooperative Oncology Group performance status of two or less, satisfactory lung shunt fractions, and no extrahepatic disease.

Between January 2019 and April 2022, fifteen consecutive patients underwent the procedure with the intention of bridging to curative resection. The cohort included seven women and eight men with a mean age of 66 years, ranging from 41 to 84. Seven had hepatocellular carcinoma, six of them at intermediate BCLC stage B and one at advanced stage C with portal vein tumor invasion, while eight had intrahepatic cholangiocarcinoma, five of whom had also received neoadjuvant gemcitabine-cisplatin chemotherapy. The mean index tumor size was a formidable 7.8 centimeters, with the largest measuring 16.2 centimeters. All patients had preserved hepatic function, and seven had underlying liver disease, including hepatitis C, alcohol-related injury, and metabolic dysfunction-associated steatotic liver disease.

Treatment planning was individualized through multidisciplinary tumor board discussion and surgical volumetric assessment. Earlier patients underwent planar macroaggregated albumin dosimetry with single-compartment calculations, while later patients benefited from SPECT/CT-based multicompartment personalized dosimetry using dedicated software. In that subgroup, the average perfused tumor absorbed dose reached 576 plus or minus 284 Gy, the average normal tissue dose was 206 plus or minus 95 Gy, the perfused fraction of the liver averaged 63 percent, and the cumulative lung absorbed dose averaged 16.4 Gy. Follow-up with triphasic CT or MRI occurred at one and three months and then at three-month intervals, with volumetric analysis at every time point using the Couinaud methodology and standardized future liver remnant calculations based on body surface area.

The results were remarkable on both fronts. Every one of the fifteen patients showed an objective tumor response by modified RECIST criteria at thirty days, with 40 percent achieving a complete response and 60 percent a partial response; by ninety days, the complete response rate rose to 53 percent as two additional partial responders converted. Meanwhile, the median future liver remnant increased by 12 percent at thirty days and 30 percent at sixty to ninety days. Median standardized future liver remnant climbed from 31 percent at baseline to 36 percent at one month and 40 percent by two to three months. Notably, hypertrophy was similar in cirrhotic and non-cirrhotic patients, and no difference emerged between hepatocellular carcinoma and cholangiocarcinoma, suggesting the volumetric effect is robust across liver conditions and tumor types.

Safety was equally encouraging. There were no major procedure-related complications, no grade three or higher hepatotoxicity by CTCAE version 5.0 criteria, and no cases of cholangitis, cholecystitis, gastric ulcers, pneumonitis, or radiation-induced liver disease. One patient experienced nausea and vomiting lasting ten days, and no patient required extended hospitalization or readmission within thirty days. This favorable profile likely reflects careful selection of patients with preserved baseline liver function and multidisciplinary evaluation, consistent with prior work showing that yttrium-90 treatment of more than 60 percent of the liver can be safe when an adequate functional remnant is maintained.

The surgical conversion rate was the standout finding. Twelve of the fifteen patients, or 80 percent, became technically eligible for curative-intent surgery, a figure substantially higher than the 16 to 20 percent conversion rates reported in earlier modified radiation lobectomy studies. Three patients were excluded by new disease progression in the contralateral liver or lungs, or inadequate remnant growth. Of the twelve eligible patients, one declined surgery and one resection was aborted because cholangiocarcinoma encased the hepatic vein confluence. Ultimately, ten patients underwent major hepatectomy, including four extended right and four standard right hepatectomies and one extended left hepatectomy, or liver transplantation in one case, at a mean of 122 plus or minus 77 days after radioembolization. Every completed resection achieved negative margins, an R0 outcome that is the surgical gold standard.

Pathology revealed a more nuanced picture. Among eight patients with available data, median tumor necrosis was 57.5 percent, ranging from 30 percent to more than 90 percent, and necrosis did not correlate with imaging response or absorbed dose. The authors attribute this variability to large, heterogeneous tumors with uneven microsphere distribution and to the relatively short interval between treatment and explantation. Despite this, overall survival after surgery remained 80 percent. Two patients with cholangiocarcinoma died within days of surgery from infectious complications, while the remaining eight resected patients showed no evidence of recurrence over an average follow-up of 39 months. Median overall survival was 61 months for hepatocellular carcinoma patients but only 19 months for those with cholangiocarcinoma, underscoring that tumor biology, not technical success, remains the dominant determinant of long-term outcome.

The study has clear limitations: it was retrospective, single-center, and small, with heterogeneous dosimetry methods and no comparator group receiving portal vein embolization or chemoembolization. Yet the message is compelling. Modified radiation lobectomy achieved universal tumor response, meaningful remnant hypertrophy, and an 80 percent surgical eligibility rate in patients whose tumors were once deemed unresectable, all with an excellent safety profile. The findings echo larger evidence, including the updated DOSISPHERE-01 analysis and the prospective PROACTIF cohort, showing that patients who reach curative surgery after yttrium-90 therapy enjoy substantially better survival than those managed nonoperatively. Larger prospective trials comparing modified radiation lobectomy with established bridging strategies are still needed, but for carefully selected patients with large primary liver cancers, this single-procedure approach may be transforming the boundary between inoperable and curable.

Subject of Research: Modified yttrium-90 radiation lobectomy as a bridge to curative surgery for primary liver cancer

Article Title: Modified radiation lobectomy as a bridge to curative surgery: tumor response, future liver remnant hypertrophy, and surgical outcomes

Article References: Malavia, M., Lindquist, J., Marchak, K., Eliason, G., Trivedi, P., & Casadaban, L. (2026). Modified radiation lobectomy as a bridge to curative surgery: tumor response, future liver remnant hypertrophy, and surgical outcomes. CVIR Oncology, 2(1), Article 29. https://doi.org/10.1007/s44343-026-00059-x

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00059-x

Keywords: modified radiation lobectomy, yttrium-90 radioembolization, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, future liver remnant hypertrophy, liver resection, radiation segmentectomy, portal vein embolization, surgical conversion, tumor response, interventional radiology, liver cancer